Our ambition is to follow the science to discover, develop and deliver life-changing treatments that transform outcomes and increase the potential for cures.

We are leading a revolution in oncology to redefine cancer care.

Our ambition is to transform care for billions of people living with chronic diseases and deliver long-lasting immunity.

We are working to intervene earlier to protect vital organs, 减缓或逆转疾病进展, and achieve remission for often degenerative, debilitating and life-threatening conditions, 所以更多的人可以生活得更好, 更健康的生活.

Our mission remains to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines as well as supportive technologies and healthcare services.
 

As we expand the reach of our medicines, our growing pipeline of investigational molecules represents continued innovation on behalf of rare disease patients.

Building diverse talent and critical capabilities, and creating a culture of high performance.

2023年成就:

76%

of employees stated they believe AstraZeneca performs as an enterprise team.

Ensuring our employees, managers and teams have the potential to develop and grow.

2023年成就:

88%

of employees stated they believe we are building a culture of lifelong learning and development.

Focusing on delivering our inclusion and diversity strategy, and learning and development programmes.

2023年成就:

50.1%

of our senior roles are filled by women.

10个以上,000 rare diseases are estimated to exist today, but fewer than 10% have approved treatment options. Rare disease community members face many unique challenges in pursuing equitable access to healthcare. We believe people with rare diseases deserve the same attention and investment to find and access therapies as anyone else. As we expand the geographies where our rare disease medicines are available, we continue to build relationships with patient communities early in our development programmes to better understand their needs.

PHSSR是一个非盈利组织, multisector, global collaboration with a unified goal of building more sustainable and resilient health systems, 活跃在30多个国家. In 2023, PHSSR published its second Summary Report with insights from 18 countries, and launched research on seven new Asia-Pacific countries. PHSSR also established an EU expert advisory group, to support EU policymakers in improving policies on prevention and early detection of NCDs.

Our 健康心脏非洲方案 is committed to reducing hypertension and the burden of CV disease, aiming to reach 10 million people with elevated blood pressure across Africa by 2025. We work with local and global partners to raise awareness and offer training, 筛选和降低治疗成本, 在适用情况下. In 2023, the programme launched in eight of 10 planned grant countries, in addition to the existing nine countries of operation.

The multi award-winning 青少年健康计划 (YHP) aims to empower young people to make more informed choices about their health and catalyse a global, 青年领导的倡导运动, supported by community programmes and research. It helps to develop young leaders and is focused on vulnerable and under-resourced communities in 40 countries. Through partnerships with more than 50 non-profit partners around the world, 包括联合国儿童基金会, the YHP promotes health literacy and policy action. In 2023, YHP won the Better Society Award for Partnership with an International Charity together with UNICEF.